Why are Telix Pharmaceuticals shares on the slide today?

The initial reaction to Telix Pharmaceuticals Ltd (ASX: TLX)’s announcement of a $3.3 billion merger with German company ITM appears lukewarm, with its shares falling more than 6%.

Building a nuclear medicine powerhouse

The Australian company said in a statement to the ASX that it would pay ITM shareholders an upfront payment of US$1.65 billion, with additional contingent payments of US$700 million.

ITM, Telix said, is the world’s leading supplier of therapeutic radioisotopes and the only producer of globally-scaled, commercial-grade lutetium-77.

Telix said regarding the deal:

The merger will further strengthen Telix’s leadership as a vertically integrated radiopharmaceutical company with the capabilities required to develop, manufacture and deliver innovative treatments to patients globally. The combined organisation will be uniquely positioned as a radiopharmaceutical industry leader, differentiated by a world-class scaled isotope manufacturing business with a validated global distribution network, a market-leading commercial precision medicine platform and the industry’s most extensive therapeutic radiopharmaceutical pipeline.

Telix said ITM grew at a compound annual rate of 40% from 2021 to 2025 and generated US$273 million in revenue in 2025.

Telix added that the global market for radioisotopes was growing, with the nuclear medicine market expected to be worth US$34 billion by 2034.

Telix Managing Director Dr Christian Behrenbruch said:

This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures. ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation. We have enjoyed a close working relationship with ITM for many years and there is strong management alignment for the rationale behind this transaction. By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector.

Telix shares were 6.1% lower on the news at $16.77.

Brokers bullish on Telix Pharmaceuticals shares

Morgan Stanley recently valued the company at $23 per share following the US Food & Drug Administration approving Telix’s new drug, Pixclara, an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

RBC Capital Markets also released a research note at the time, valuing the company at $19.

RBC estimated the total addressable market for Pixclara’s current use to be US$140 to US$160 million per year.

The broker added:

Assuming a penetration rate of ~60% in FY35, we estimate Pixclara’s first indication would be valued at $0.56/share with further upside potential of $0.62/share if Pixclara achieves ~80% penetration. If the company is successful in securing approval to expand Pixclara’s indication to include brain metastases, we estimate this could potentially add as much as ~$3.85/share to our price target.

The post Why are Telix Pharmaceuticals shares on the slide today? appeared first on The Motley Fool Australia.

More reading

• Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best?
• Telix Pharmaceuticals: ITM merger builds a sector leader
• These are the 10 most shorted ASX shares
• ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike
• Forget CSL shares, I’d buy this ASX biotech stock instead

Motley Fool contributor Cameron England has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.